{
    "medicine_id": "7c742c3c6058e4e3b349ebcc78d133e32246cf78",
    "platform_id": "DB04967",
    "metadata": {
        "name": "Potiga 50 mg 1 Tablet film coated",
        "composition": "50 mg 1 Lucanthone",
        "clinical_particulars": {
            "therapeutic_indications": "Intended for use as a radiation sensitizer in the treatment of brain cancer",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Although lucanthone has structural and biochemical similarities to Actinomycin D it has no hematological or gastro intestinal toxicity at clinically tolerated doses In trials Lucanthone was found to be safe practical and effective and was proposed for use in clinical protocols for the treatment of cancer The specificity of lucanthone in combination with radiation for the treatment of brain tumors arises from the fact that lucanthone acts preferentially on cycling cells most of the normal brain cells are non cycling and the fact that lucanthone crosses the blood brain barrier efficiently",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}